Bayesian Capital Management LP Buys New Stake in Intrexon Corporation (XON)
Bayesian Capital Management LP bought a new stake in shares of Intrexon Corporation (NYSE:XON) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,400 shares of the biotechnology company’s stock, valued at approximately $299,000.
Several other institutional investors have also made changes to their positions in XON. Pacer Advisors Inc. grew its stake in Intrexon Corporation by 21.6% during the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 1,305 shares during the period. SG Americas Securities LLC bought a new stake in Intrexon Corporation in the first quarter worth approximately $164,000. Federated Investors Inc. PA bought a new stake in Intrexon Corporation in the second quarter worth approximately $172,000. Cullinan Associates Inc. bought a new stake in Intrexon Corporation in the second quarter worth approximately $201,000. Finally, John G Ullman & Associates Inc. acquired a new position in Intrexon Corporation in the second quarter valued at approximately $212,000. Institutional investors own 82.11% of the company’s stock.
A number of equities analysts have issued reports on XON shares. Northland Securities set a $30.00 price target on Intrexon Corporation and gave the stock a “buy” rating in a report on Monday, August 7th. BidaskClub downgraded shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Zacks Investment Research lowered shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $37.60.
Intrexon Corporation (NYSE XON) opened at 19.41 on Tuesday. The company’s market cap is $2.34 billion. Intrexon Corporation has a 52-week low of $17.03 and a 52-week high of $32.90. The stock’s 50 day moving average is $18.91 and its 200-day moving average is $21.13.
Intrexon Corporation (NYSE:XON) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The business had revenue of $54.40 million for the quarter, compared to the consensus estimate of $57.17 million. During the same period in the previous year, the firm earned ($0.42) EPS. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities research analysts predict that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.
In related news, Director Robert B. Shapiro purchased 2,850 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was bought at an average cost of $17.50 per share, with a total value of $49,875.00. Following the completion of the purchase, the director now directly owns 43,157 shares in the company, valued at $755,247.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dean J. Mitchell purchased 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average cost of $18.33 per share, with a total value of $91,650.00. Following the completion of the purchase, the director now owns 18,103 shares of the company’s stock, valued at $331,827.99. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 144,569 shares of company stock valued at $2,719,429. Corporate insiders own 56.30% of the company’s stock.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.